3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Multiple Myeloma
36
Neoplasms, Plasma Cell
12
Prostatic Neoplasms
4
Neoplasms
3
Lymphoma, Mantle-Cell
3
Immunoglobulin Light-chain Amyloidosis
3
Central Nervous System Neoplasms
3
Waldenstrom Macroglobulinemia
2
Sarcoma
2
Recurrence
2
Rectal Neoplasms
2
Neuroblastoma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Lung Neoplasms
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia
2
Glioma
2
Glioblastoma
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Amyloidosis
2
Adenocarcinoma of Lung
2
Renal Insufficiency, Chronic
1
Renal Insufficiency
1
Polyneuropathies
1
Paraproteinemias
1
Neurotoxicity Syndromes
1
Motor Activity
1
Interventions
Trastuzumab
3
Sugammadex
2
Neostigmine
2
Cisplatin
2
valrubicin
1
tucatinib
1
pembrolizumab
1
niraparib
1
enfortumab vedotin
1
avelumab
1
atezolizumab
1
Surveys and Questionnaires
1
Sunitinib
1
Standard of Care
1
Rocuronium
1
Pemetrexed
1
Paclitaxel
1
Nephroureterectomy
1
Neoadjuvant Therapy
1
Mitomycin
1
Lymph Node Excision
1
Glycopyrrolate
1
Gemcitabine
1
GSK-3326595
1
Fulvestrant
1
Docetaxel
1
Cetuximab
1
Afatinib
1
Administration, Intravesical
1
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Urologic Neoplasms
×
Thalidomide
×
Clear all
No trials found.